Author:
Madhusudan S,Protheroe A,Propper D,Han C,Corrie P,Earl H,Hancock B,Vasey P,Turner A,Balkwill F,Hoare S,Harris A L
Publisher
Springer Science and Business Media LLC
Reference33 articles.
1. Bedikian AY, Plager C, Stewart JR, O'Brian CA, Herdman SK, Ross M, Papadopoulos N, Eton O, Ellerhorst J, Smith T (2001) Phase II evaluation of bryostatin-1 in metastatic melanoma. Melanoma Res 11: 183–188
2. Benoy I, Salgado R, Colpaert C, Weytjens R, Vermeulen PB, Dirix LY (2002) Serum interleukin 6, plasma VEGF, serum VEGF, and VEGF platelet load in breast cancer patients. Clin Breast Cancer 2: 311–315
3. Brockstein B, Samuels B, Humerickhouse R, Arietta R, Fishkin P, Wade J, Sosman J, Vokes EE (2001) Phase II studies of bryostatin-1 in patients with advanced sarcoma and advanced head and neck cancer. Invest New Drugs 19: 249–254
4. Dale IL, Gescher A (1989) Effects of activators of protein kinase C, including bryostatins 1 and 2, on the growth of A549 human lung carcinoma cells. Int J Cancer 43: 158–163
5. Fowler L, Everitt J, Stevens JL, Jaken S (1998) Redistribution and enhanced protein kinase C-mediated phosphorylation of alpha- and gamma-adducin during renal tumor progression. Cell Growth Differ 9: 405–413
Cited by
42 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献